A prospective comparison of mid-term outcomes in patients treated with heart transplantation with advanced age donors versus left ventricular assist device implantation

Autor: Enrico Ammirati, Marisa Varrenti, Manlio Cipriani, Tiziano Colombo, Filippo Milazzo, Fabrizio Oliva, Aldo Cannata, E. Benazzi, Maria Frigerio, Andrea Garascia, M.P. Gagliardone, Claudio Russo, Giovanna Pedrazzini
Přispěvatelé: Ammirati, E, Cipriani, M, Varrenti, M, Colombo, T, Garascia, A, Cannata, A, Pedrazzini, G, Benazzi, E, Milazzo, F, Oliva, F, Gagliardone, M, Russo, C, Frigerio, M
Rok vydání: 2015
Předmět:
Pulmonary and Respiratory Medicine
Male
medicine.medical_specialty
Heart-Assist Device
medicine.medical_treatment
Advanced heart failure
Population
Left ventricular assist device
030204 cardiovascular system & hematology
Follow-Up Studie
03 medical and health sciences
0302 clinical medicine
Age
Risk Factors
Medicine
Humans
030212 general & internal medicine
Prospective Studies
education
Prospective cohort study
Survival rate
Marginal donor
Heart transplantation
Heart Failure
education.field_of_study
business.industry
Risk Factor
Hazard ratio
Middle Aged
equipment and supplies
medicine.disease
Tissue Donors
Surgery
Transplantation
Survival Rate
Prospective Studie
Treatment Outcome
Italy
Heart failure
Ventricular assist device
Heart Transplantation
Female
Heart-Assist Devices
Cardiology and Cardiovascular Medicine
business
Human
Follow-Up Studies
Zdroj: Interactive cardiovascular and thoracic surgery. 23(4)
ISSN: 1569-9285
Popis: OBJECTIVES In Europe, the age of heart donors is constantly increasing. Ageing of heart donors limits the probability of success of heart transplantation (HTx). The aim of this study is to compare the outcome of patients with advanced heart failure (HF) treated with a continuous-flow left ventricular assist device (CF-LVAD) with indication as bridge to transplantation (BTT) or bridge to candidacy (BTC) versus recipients of HTx with the donor's age above 55 years (HTx with donors >55 years). METHODS we prospectively evaluated 301 consecutive patients with advanced HF treated with a CF-LVAD (n = 83) or HTx without prior bridging (n = 218) in our hospital from January 2006 to January 2015. We compared the outcome of CF-LVAD-BTT (n = 37) versus HTx with donors >55 years (n = 45) and the outcome of CF-LVAD-BTT plus BTC (n = 62) versus HTx with donors >55 years at the 1- and 2-year follow-up. Survival was evaluated according to the first operation. RESULTS The perioperative (30-day) mortality rate was 0% in the LVAD-BTT group vs 20% (n = 9) in the HTx group with donors >55 years (P = 0.003). Perioperative mortality occurred in 5% of the LVAD-BTT/BTC patients (n = 3) and in 20% of the HTx with donors >55 year group (P = 0.026). Kaplan-Meier curves estimated a 2-year survival rate of 94.6% in CF-LVAD-BTT vs 68.9% in HTx with donors >55 years [age- and sex-adjusted hazard ratio (HR) 0.25; 95% confidence interval (CI) 0.08-0.81; P = 0.02 in favour of CF-LVAD]. Considering the post-HTx outcome, a trend in favour of CF-LVAD-BTT was also observed (age- and sex-adjusted HR 0.45; 95% CI 0.17-1.16; P = 0.09 in favour of CF-LVAD), whereas CF-LVAD-BTT/BTC showed a similar survival at 2 years compared with HTx with donors >55 years, both censoring the follow-up at the time of HTx and considering the post-HTx outcome. CONCLUSIONS Early and mid-term outcomes of patients treated with a CF-LVAD with BTT indication seem better than HTx with old donors. It must be emphasized that up to 19% of patients in the CF-LVAD/BTT group underwent transplantation in an urgent condition due to complications related to the LVAD. At the 2-year follow-up, CF-LVAD with BTT and BTC indications have similar outcome than HTx using old heart donors. These results must be confirmed in a larger and multicentre population and extending the follow-up.
Databáze: OpenAIRE
Externí odkaz: